NEW YORK (GenomeWeb News) — Certain members of Tripos’ management team may consider buying the firm’s Discovery Research business if bids by Provid Pharmaceuticals or other parties fall through, the company said last week.
 
Tripos made its remarks as the company said that fourth-quarter revenues declined 8 percent as R&D spending fell 35 percent and loss narrowed 46 percent.
 
Total receipts for the three months ended Dec. 31, 2006, fell to $6.7 million from $7.2 million year over year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.